Navigation Links
Genova files patent for new prostate cancer treatment
Date:9/8/2009

NEW YORK, Sept. 8 /PRNewswire-FirstCall/ - (OTCBB: GVBP.OB) - GENova Biotherapeutics, Inc., ("GENova"), is pleased to announce that it has filed a patent for a novel peptide that disrupts the advance of prostate cancer and thus has blockbuster potential as a new anti-cancer drug.

The peptide, called Prostaganin, is a 21-amino compound which is highly reactive to prostate cancer cells, and has the ability to specifically target them. In laboratory experiments, Prostaganin has demonstrated an ability to preferentially bind to and disrupt certain negatively charged components of the membranes of prostate cancer cells.

Prostaganin thus has tremendous potential as a superior new form of treating prostate cancer. Current treatment methods such as surgery, radiation and chemotherapy are outmoded, unsatisfactory, and have severe side effects. Prostaganin offers a positive alternative. The peptide, bio-engineered from naturally occurring compounds in the human body, can target and destroy cancerous cells, whilst leaving surrounding healthy tissues intact, and causing no undesirable side effects. Further development of this novel peptide could revolutionize the way people fight cancer.

The demand for new and better treatments for prostate cancer has never been higher. Prostate cancer presently accounts for 30% of all the major cancers in men. The Prostate Cancer Foundation states that prostate cancer is the cancer with the largest expected increase in the next decade, and that annual incidence of the cancer will rise to 300,000 cases in the U.S. alone by 2015.

"Prostaginin represents a significant milestone in GENova's business agenda to acquire patents for the most innovative new cancer treatments," says Aaron Whiteman, CEO of GENova, "But most importantly, it represents a new generation of cancer treatments that could save millions of lives, and treat prostate cancer in men with no side effects or adverse effects on quality of life. Th
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. GENova names Dr. John Savin as Vice President
2. GENova names Aaron Whiteman as CEO
3. Sun Pharmaceutical Files HSR Application for Taro Tender Offer
4. InfoLogix Files Preliminary Proxy Statement in Connection with Special Meeting of Its Stockholders to Approve Recapitalization Plan
5. VirtualHealth Technologies Files 8k Related to the August 17th Announcement of Private Access Payment and Document Modification
6. Profiles International Releases New Study Identifying Key Factors for Strategic Workforce Planning
7. "Med Records to Go" Stores Document and Image Files of Medical Facilities for Emergency Viewing
8. AMDL Inc. Files Notification of Late Filing for Form 10-Q
9. Texas Law Firm Files Multiple Suits Against Medtronic as Deadline Approaches
10. Star Scientific Files Second Quarter Financial Results; Rock Creek Pharmaceuticals Reports Early Promising Results in Studies Assessing Safety and Viability of Active Components for a Non-Nicotine Nutraceutical (CigRx(TM))
11. Vitamin Shoppe Files Registration Statement for Initial Public Offering of Common Stock

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)..., WASHINGTON, Dec. 4 As...ul plan, Family Research Council (FRC) today annou...phones in Louisiana to survey each household on pr...clude abortion funding, rationing, higher taxes, a...n. Survey participants who express opposition to ...
(Date:12/4/2009)... PACIFIC PALISADES, Calif., Dec. 4 ... your loved ones something they can be proud of - ...cs® Physician-Formulated Anti-Wrinkle Moistur...ul appearance made possible with an all-in-one cre...magenics Ultra-Intensive Anti-Wrinkle Beauty Moist...
(Date:12/4/2009)...ork profile usually conveys true personality, stud...ws) -- Does your profile on an online social netwo...s are good that it does, reports a new study, whic...ves instead of idealized identities. , "I was ...assumption is that people are using their profiles...
(Date:12/4/2009)... BATESVILLE, Ind., Dec. 4 /PRNewswire-FirstCall/ -...ounced its fiscal 2010 first quarter dividend of $...ll-Rom,s Board of Directors on December 3, 2009, a...s of record as of December 17, 2009. ,, AB...leading worldwide manufacturer and provider of med...
(Date:12/4/2009)..., UNION, N.J., Dec. 4 PLUS Diagn...pecialty anatomic pathology services with the laun... new service completes the company,s expansion fro...omic pathology company offering diagnostic service...troenterology, urology and now hematology/oncology...
Breaking Medicine News(10 mins):Health News:FRC Announces Campaign to Call Every Louisiana Household, Urging Opposition to Health Care Takeover 2Health News:Give the Gift of Beautiful Skin for the Holiday Season 2Health News:Online Identities Likely to Match Reality 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 2Health News:PLUS Diagnostics Launches Hematology/Oncology Diagnostic Services 3
... Disaster Giving Program Recognized for,Their Fina...stav,created a critical need for overnight shelter... respond following Gustav,s landfall along the Gul...eason 2008., Members of the Red Cross Annual Disa...
...nternational Society for Cultural and Activity Res... California, San Diego, Sept. 8-13, 2008. Nearly 1... conference with others participating from around ...ns of human practices where the context, or enviro...
...eeking active participation in their communities h...erican life. As a result, civic engagement can now...ng to an article in the latest issue of The Gero...directly impact the local community. They also arg...
...3, 2008 -- Getting pregnant with her first child w...ttesville, Va. experienced a miscarriage during he...ver have another baby. When she decided to enter a... a miracle. , "To our great surprise we were bles...
...d levels within 6 hours for participants in phase ...y News) -- An experimental gout drug called peglot...target levels within a few hours in most patients....ug. , The phase II clinical trial included 41 pat...
... 2008 The U.S. Pharmacopeial (USP) Convention,s 2...n Kansas City, Mo., September 24 to 26. The meetin...ts responsible for establishing internationally re...ured Medicines, Food Ingredients and Dietary Suppl...
Other Medicine News:Health News:American Red Cross Responds to Hurricane Gustav 2Health News:American Red Cross Responds to Hurricane Gustav 3Health News:ISCAR, world-wide conference on role of culture in human development, convenes at UCSD 2Health News:Experts establish baseline for civic engagement among retirees 2Health News:Acupuncture may hold promise for women with hormone disorder 2Health News:New Drug Helps Relieve Gout 2Health News:USP's 2008 Annual Scientific Meeting to convene scientific experts from around the world 2
(Date:12/3/2009)..., , DOYLESTOWN, Pa., Dec. 3 /PRNewswi...he Quigley Corporation, (Nasdaq: QGLY ) www.quig...mpleted its evaluation of its opportunities to dev...and has concluded that it is in its best interests...tplace, which may include but are not limited to i...
(Date:12/3/2009)..., , WILMINGTON, Del., Dec. 3 /PRNewswire...ing in pharmaceutical risk management and optimal ...day, Dec. 9, on the FDA,s draft guidance on REMS -...d its implications for REMS lifecycle management. ...Rx and an expert on REMS and risk management progr...
(Date:12/3/2009)..., , DURHAM, N.C., Dec. 3 /PRNewswire-USNew... role of healthcare information technologies in th...ne has created the Duke Center for Health Informat...formatics. DCHI will oversee an innovative interdi... a new generation of physicians, nurses and health...
Breaking Medicine Technology:Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Duke Medicine to Train Healthcare Professionals in Health Informatics 2Duke Medicine to Train Healthcare Professionals in Health Informatics 3Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 1Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 2Novel Information about Vulnerable Coronary Artery Plaque to be Presented at Transcatheter Cardiovascular Therapeutics 28TCT 29 2009 57787 3Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 1Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 2Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 3Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 4Photo 3A Moms To Be Can Eat Well Even on a Budget 57785 5Clean Hands Report Card 28R 29 3A Americans Get a B on Hand Hygiene 57783 1Clean Hands Report Card 28R 29 3A Americans Get a B on Hand Hygiene 57783 2Clean Hands Report Card 28R 29 3A Americans Get a B on Hand Hygiene 57783 3
...of cost-effective and rapidly deployed ...CKVILLE, Md., Sept. 29 Novavax, Inc.,(Nasdaq: NV... meeting of the,Clinton Global Initiative ("CGI") ...H5N1 avian influenza vaccine and a seasonal influe...inant virus-like particles ("VLPs").,As one of the...
... - Results Presented at World Stroke Congress in ..., a biotechnology company,focused on novel therapi...nounces positive results from its MITI IV Phase II...cacy of microplasmin when administered,intravenous... microplasmin,was generally well tolerated and als...
Other Medicine Technology:NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting 2NOVAVAX Featured at Clinton Global Initiative 2008 Annual Meeting 3ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 2ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 3ThromboGenics Announces Promising Results of MITI IV Phase II Trial in the Treatment of Acute Stroke with Microplasmin 4
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
...is a national reference laboratory and a worldwide...lopment. ARUP offers an extensive test menu of hig...nd anatomic pathology. Owned by the University of ... half of the nation's university teaching hospital...
Medicine Products: